TSTickerStar
Company alerts/JUNS
JUNS company alerts

JUNS updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for JUNS. Subscribe to JUNS alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent JUNS alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

SEC filingSEC filing

JUNS 10-Q filed 2026-11-16 | Key takeaways

JUNS filed its 10-Q; the most relevant disclosure change is added Business combinations: Company entered a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. on July 20, 2026 for exclusive U.S. rights to ALA-002, a proprietary MDMA formulation. Upfront consideration of $3,333,333 comprised of $1,500,000 cash and $1,83.

Read source-backed brief